Articles tagged with Oncology
A study found that patients with missing case information in the SEER database have lower survival rates and are more likely to be from rural or socioeconomically disadvantaged backgrounds. The researchers suggest using multiple data sources to mitigate this issue.
Researchers conducted a meta-analysis of nine randomized clinical trials to evaluate the effectiveness of methylphenidate-type psychostimulants in reducing cancer-related fatigue. The study found significant improvements in fatigue scores, with benefits increasing over time.
A rare case of esophageal adenocarcinoma is reported, where the tumor grew outside the esophagus and invaded the thoracic spine, causing spinal cord compression. The patient initially had normal endoscopic findings, highlighting the challenge in detecting rare extraluminal growth patterns.
A new study found that diaphragmatic dome height on chest X-rays is a practical prognostic marker for predicting long-term outcomes and respiratory-related deaths in lung cancer patients with breathing disorders. Lower DDH before surgery was associated with poorer survival rates.
A rare case of high-grade laryngeal leiomyosarcoma was successfully treated with extended laryngectomy, left neck dissection, and adjuvant chemotherapy. Complete surgical excision remains the cornerstone of therapy, while multidisciplinary-guided adjuvant treatment may benefit selected high-grade or high-risk patients.
At ASCO 2026, City of Hope experts will present research on innovative treatments for various types of cancer. Their findings include the efficacy and safety of immunotherapy combinations, as well as the potential use of CBM588 to enhance immune checkpoint blockade in metastatic renal cell carcinoma.
A new national clinical trial investigates whether fewer invasive bladder exams can safely reduce discomfort and improve quality of life for patients with bladder cancer. Led by Dartmouth Cancer Center, the study aims to show that fewer procedures are just as effective at keeping patients healthy.
A new editorial proposes the use of agentic AI systems to address cancer-related malnutrition, a prevalent issue affecting up to 80% of patients. These systems aim to coordinate multiple functions simultaneously and support ongoing clinical decision-making throughout treatment.
A rare case of a small bowel GIST harboring concurrent KIT exon 9 duplication and SDHC mutation showed a strong response to high-dose imatinib, despite the presence of the SDHC mutation. Integrated molecular interpretation is crucial in GIST management.
The ERASur clinical trial is investigating whether total ablative therapy can improve overall survival in patients with newly diagnosed, limited metastatic colorectal cancer. The study has reached one-third patient accrual milestone, signaling strong momentum.
Dr. Aparna Bhaduri receives $750k Pershing Square Sohn Cancer Prize for her innovative glioblastoma research. Her advanced human organoid models reveal how tumors interact with the immune system and brain cells, driving tumor aggressiveness.
The review highlights how retrieval-augmented generation can improve the accuracy, transparency, and clinical reliability of AI tools in cancer care. RAG-enhanced systems produced more accurate results than standard AI models across multiple studies.
Researchers at UTHealth Houston have discovered a new target for metastatic breast cancer treatments using experimental peptide therapy. The study found that the peptide BLMP6 targets fibulin-4, a protein expressed in high levels in metastatic breast cancers.
A new study found a clear shift in mortality trends in multiple myeloma closely parallels major therapeutic advances. Targeted therapies, including immunomodulatory drugs and CAR T-cell therapies, have significantly improved disease control and induced deep responses.
NCCN staff received awards and publications for advancing quality cancer care, including Dr. Alyssa Schatz's Leadership in Policy, Equity, and Advocacy award and Faviolla Baez-Cruz's publication on biochemical research. The National Comprehensive Cancer Network is recognized for its work to improve outcomes for people with cancer.
A first-in-human clinical trial found that setidegrasib, a targeted therapy drug, demonstrated early antitumor activity in advanced lung and pancreatic cancers. The therapy shrank tumors and delayed disease progression in some patients, providing a potential new treatment approach for KRAS G12D-driven cancers.
Independent academic clinical trials are essential for improving patient outcomes, reducing inequalities in care, and strengthening healthcare systems. The Lancet Oncology Commission aims to deliver actionable recommendations to ensure these trials continue to benefit patients and society worldwide.
A new study suggests that an AI tool analyzing facial changes can serve as a prognostic biomarker for cancer prognosis. The researchers found that patients with higher biological aging rates had lower chances of survival, and the effect was strongest when photos were taken over longer intervals.
A new review found that lifestyle behaviors like physical activity and diet can positively modulate the gut microbiome of cancer patients, but these effects are often influenced by non-modifiable variables. The study also highlighted the role of intrinsic patient characteristics in shaping microbial composition.
The new NCCN Guidelines for Patients: Prostate Cancer Screening provide a comprehensive guide to evidence-based recommendations for age-specific screening. The guidelines aim to balance the benefits of early detection with the risks of unnecessary procedures, emphasizing the importance of personalized care and monitoring.
A specific region of Dicer must be activated to achieve proper cell division and reproduction, a discovery that sheds light on the regulation of this enzyme's critical role in both cancer biology and fertility. This finding opens new avenues for studying how small epigenetic changes contribute to disease.
EGFR-TKIs have significantly improved OS and quality of life for EGFR-mutant NSCLC patients. However, ongoing research is needed to refine therapies for precise individualized treatment, addressing resistance mechanisms and optimal combination strategies.
A research team at the University of Cologne discovered that the protein cFLIP can be used to override the defences of Diffuse Large B Cell Lymphoma (DLBCL) against programmed cell death. Targeting cFLIP could re-activate cell death in lymphoma cells and provide a new therapy option.
A new targeted therapy has shown strong results in preclinical studies against aggressive childhood and adult cancers, eliminating tumours and stopping cancer spread. The therapy targets the IL1RAP protein, which is found on cancer cells but largely absent from normal tissues, allowing for precise delivery of treatment.
The Keck School of Medicine of USC and Tempus are creating a system-wide framework to integrate clinical care, clinical trials, and research through AI-powered precision medicine tools. The goal is to enhance patient care and accelerate research and innovation.
A cross-sectional study of patients with de novo metastatic breast cancer found racial and ethnic disparities in disease presentation. De novo metastatic breast cancer disproportionately contributes to breast cancer mortality in the U.S., emphasizing the need for tailored interventions to improve care delivery and outcomes.
A new study from Tulane University found that extra sets of chromosomes in tumor cells make them more mobile and likely to engulf neighboring cells. This stress response triggers an abundance of proteins, reprogramming the cells for motility and phagocytosis.
A rare case of mucinous ovarian carcinoma was reported in a postmenopausal woman, initially misdiagnosed as a pelvic abscess due to nonspecific symptoms and radiologic features. The diagnosis was confirmed after advanced imaging and tumor marker assessment. Early recognition is crucial for timely diagnosis and effective treatment of th...
Researchers have found that combining pembrolizumab and lenvatinib shows promise in treating recurrent clear cell ovarian and endometrial cancers with poor responses to standard treatments. The LARA trial provides encouraging responses for patients with this rare and difficult-to-treat cancer subtype.
The MEDABIS-PRO project aims to elucidate the effects of magnetic fields on dose delivery and biological radiation in MRI-guided proton therapy. Researchers will analyze the impact of magnetic field orientations and strengths on proton beam propagation and biological effects, using computer simulations and measurements.
Researchers at the University of Colorado Anschutz discovered that cancer drugs impact a specific protein regulating taste buds. This finding could lead to new treatments preserving taste function in cancer patients.
Five fellows will receive funding for four years to study hard-to-treat pediatric cancers, reduce treatment toxicity, and develop innovative therapies. Their research focuses on Ewing sarcoma, leukemia, kidney cancer, and immune system vulnerabilities.
Researchers have identified the Prrx1 gene as a key regulator of metastatic potential in breast cancer tumors. This discovery helps explain why highly invasive cells do not always give rise to metastases, and how cells combine invasiveness and proliferation to become the most dangerous from a clinical perspective.
A study by the Alliance Foundation Trials shows that combining immunotherapy and chemotherapy before surgery can help more patients with locally advanced non-small cell lung cancer undergo complete cancer resection, improving their long-term health. The treatment also led to high rates of lymph node clearance and successful surgical re...
A rare scalp reaction resembling erosive pustular dermatosis was identified in a lung cancer patient treated with amivantamab following cranial radiotherapy. The reaction appeared to be related to impaired wound healing due to dual inhibition of EGFR and MET signaling pathways.
A nationwide study reveals that individuals with lower educational attainment are more likely to die from colorectal cancer at a younger age. The disparity in young-onset CRC mortality nearly doubled over the past three decades among those with 12 years or less education compared to those with 16 or more years of education.
Researchers at St. Jude Children's Research Hospital developed patient-derived tumor organoids that accurately reflect the biologic underpinnings of embryonal brain tumors. The models enable faster functional assays and preclinical drug testing without relying on newly obtained tumor samples, advancing the study of pediatric brain tumors.
Immunotherapy combining checkpoint inhibitors, CAR-T, CAR-NK, and cancer vaccines shows promising results in treating AML. Chemotherapy can enhance the efficacy of these treatments by reshaping the tumor microenvironment.
A clinical trial aims to evaluate whether laser therapy reduces vaginal dryness caused by breast cancer treatment. The study, REVITALIZE, plans to enroll approximately 250 women with a history of breast cancer who experience moderate to severe vaginal dryness.
Research from Alberta reveals that survivors of adolescent and young adult cancers are at double the risk of developing most types of later cancers. Lymphoma and breast cancer were found to be the most common subsequent cancers after an initial diagnosis, with breast, colorectal, and lung cancers making up 43% of cases.
Oncology services are often excluded from emergency health priorities, resulting in delayed diagnosis and treatment interruptions. Vulnerable populations, including women and children, face advanced disease stages due to delays in care.
Dr. Jennifer Wargo has made groundbreaking contributions to defining the interplay between the microbiome, oncogenic signaling and tumor immunity, with a focus on immunotherapy responses and mechanisms of targeted therapy resistance in melanoma.
A 76-year-old woman developed spinal mixed histiocytosis after multiple relapses of BRAF-mutated unifocal skull Langerhans cell histiocytosis. She was treated successfully with targeted therapy, highlighting the importance of routine PET/CT screening and genetic testing for refractory cases.
This study established a novel method for amplifying the entire HPV16 genome, demonstrating high sensitivity and specificity. The overlapping extension polymerase chain reaction (PCR) approach enabled effective amplification of samples as low as 2 copies/μL, with stable results at higher concentrations.
The phase III NRG GY019 trial found that paclitaxel/carboplatin followed by letrozole is the standard treatment for patients with stage II-IV low-grade serous ovarian carcinoma. The study also showed that letrozole monotherapy did not demonstrate non-inferiority to the combination, but was associated with fewer serious side effects.
A new study maps how rare mixed tumors evolve into hybrid cell states and immune-protected neighborhoods, pointing to new ways to detect and treat combined small-cell lung cancer. The findings reveal that these tumors do not arise from two separate cancers but rather from a single ancestral cell that evolves over time.
A national study found that unmet health-related social needs are associated with lower colorectal cancer screening rates, particularly among adults aged 50-64. Addressing these needs may support age-specific strategies to improve screening rates.
Several open-source AI models consistently produced summaries that were more comprehensive than physician-written versions, particularly in capturing molecular and genetic findings. The study found that Llama 3.1 and DeepSeek performed best among the six evaluated models.
Nancy L. Lewis, MD, MBS, FACP, a renowned biomedical researcher and clinical trials expert, has been appointed as the new Chief Scientific Officer of the National Comprehensive Cancer Network (NCCN). She will oversee NCCN's programs to advance clinical trials and improve cancer care outcomes globally.
UCLA investigators present new research on targeted drug delivery for colorectal cancer, COVID-19's impact on breast cancer outcomes, and AI in cancer diagnosis. These studies offer insights into overcoming drug resistance, enhancing immune responses, and improving outcomes for patients with difficult-to-treat cancers.
Researchers generated a comprehensive view of DNA methylation abnormalities in human MDS HSCs, uncovering a novel TET2-GFI1 axis that suppresses malignant transformation. The study identifies key hematopoietic regulators and provides a panoramic view of DNA methylation disruption in MDS.
The European Association of Nuclear Medicine (EANM) has joined the EMUC26 congress to promote nuclear medicine expertise in urological cancers. The event will bring together healthcare professionals from various disciplines to discuss current practices and emerging innovations.
The study found that immune checkpoint inhibitors significantly improved key clinical outcomes, including disease-free survival and distant metastasis-free survival. However, no clear improvement in overall survival was observed across studies, highlighting the need for careful patient selection and monitoring.
Researchers developed an AI model to predict Barrett's esophagus recurrence after endoscopic eradication therapy. The tool shows high accuracy in identifying patients at risk and detecting when recurrence is likely to occur.
A new, cost-effective blood test detects liver, lung, ovarian, stomach cancers, and various non-cancer conditions by analyzing DNA fragments in the bloodstream. The test achieved high accuracy rates for multi-cancer detection and tissue-of-origin identification.
A new study from Oregon State University has found a way to treat both lung cancer and associated muscle-wasting cachexia using lipid nanoparticles. The treatment involves loading the nanoparticles with follistatin messenger RNA, which triggers cells to produce the protein, promoting muscle tissue growth while inhibiting tumors.
A new review analyzes how glioma classification research has evolved across clinical, molecular, and social domains. The study highlights the prominent role of DNA methylation profiling and advanced imaging techniques in molecular biomarker-based classification models, while finding social factors to be relatively scarce.
The Alliance for Clinical Trials in Oncology is enrolling adolescent and young adult cancer patients in various trials, including genetic services and treatment studies. These trials aim to address longstanding gaps in care and improve outcomes for AYAs with cancer.
A new article in JMIR Publications showcases precision oncology's success, where individualized multi-drug regimens improve treatment responses and survival rates for patients with advanced cancers. The study found that closely matching drug therapies to tumor mutations leads to better outcomes, while also offering a safer profile.
The NCCN Foundation recognizes five young investigators for their promising research on cancer innovation, providing $100,000 grants to advance their work and strengthen the pipeline for cancer success.